氯硝酰胺杂质3 | 16739-20-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯硝酰胺杂质3
• 英文名称: p-niclosamide
• 英文别名: 2',3-dichloro-4'-nitro-salicylanilide；3-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide
• CAS: 16739-20-1
• 化学式: C₁₃H₈Cl₂N₂O₄
• 分子量: 327.124
• InChiKey: NROPOQBHSPADAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Dry reactive processing
  申请人：UNIROYAL CHEMICAL COMPANY, Inc.

  公开号：EP0238240A2

  公开（公告）日：1987-09-23

  A method of preparing a water-soluble or water-­dispersible pesticidal composition is described. The pesticidal composition is prepared in a continuous process by intimately mixing a Bronsted acid precursor of the pesticidally active compound with a Bronsted base under reaction conditions in an extruder. The reaction is performed with minimal solvent and under conditions where the water of reaction volatilizes during the course of the reaction.

  本文描述了一种制备水溶性或水分散性杀虫组合物的方法。该杀虫组合物是在挤压机中，在反应条件下，通过将杀虫活性化合物的勃朗斯特酸前体与勃朗斯特碱紧密混合，以连续工艺制备的。反应是在溶剂极少和反应水在反应过程中挥发的条件下进行的。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Methods and compositions for treating conditions associated with an abnormal inflammatory response
  申请人：First Wave Bio, Inc.

  公开号：US10772854B2

  公开（公告）日：2020-09-15

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES
  申请人：Fogelman Alan M.

  公开号：US20090163408A1

  公开（公告）日：2009-06-25

  This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues when orally administered in conjunction with a peptide pharmaceutical (e.g., a class A amphipathic helical peptide as described herein) significantly increases the bioavailability of that peptide. Methods of peptide delivery using such “delivery agents” and pharmaceutical formulations are provided.
• SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS
  申请人：Fogelman Alan M.

  公开号：US20110183889A1

  公开（公告）日：2011-07-28

  This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide.